Abstract
Male gender is a risk factor for cardiovascular diseases. Testosterone being the main male sex hormone is therefore believed to be responsible for the deleterious effect of the male. However, there are recent studies showing that testosterone level is lower in patients with ischemic heart diseases, and testosterone treatment alleviates the symptoms. Earlier studies showed that functional androgen receptors are present in the heart and that testosterone acts directly at the myocardium. There is increasing evidence to suggest testosterone confers cardioprotection by direct action on the myocardium. Here, we review the recent literature on association between testosterone and myocardial ischemia in males, and the signal transduction mechanisms that mediate the action of testosterone in the heart. The studies reviewed in this article provide evidence that testosterone may confer protection via a varieties of mechanisms, which may be both genomic and non-genomic. Further studies are warranted to further delineate the integration of signaling mechanisms and to explore the possibility of using testosterone in the aging male population with ischemic heart diseases.
Keywords: Testosterone, myocardial ischemia, adrenoceptor, calcium homeostasis
Cardiovascular & Hematological Disorders-Drug Targets
Title: Testosterone and Cardioprotection Against Myocardial Ischemia
Volume: 7 Issue: 2
Author(s): Sharon Tsang, Jing Liu and Tak Ming Wong
Affiliation:
Keywords: Testosterone, myocardial ischemia, adrenoceptor, calcium homeostasis
Abstract: Male gender is a risk factor for cardiovascular diseases. Testosterone being the main male sex hormone is therefore believed to be responsible for the deleterious effect of the male. However, there are recent studies showing that testosterone level is lower in patients with ischemic heart diseases, and testosterone treatment alleviates the symptoms. Earlier studies showed that functional androgen receptors are present in the heart and that testosterone acts directly at the myocardium. There is increasing evidence to suggest testosterone confers cardioprotection by direct action on the myocardium. Here, we review the recent literature on association between testosterone and myocardial ischemia in males, and the signal transduction mechanisms that mediate the action of testosterone in the heart. The studies reviewed in this article provide evidence that testosterone may confer protection via a varieties of mechanisms, which may be both genomic and non-genomic. Further studies are warranted to further delineate the integration of signaling mechanisms and to explore the possibility of using testosterone in the aging male population with ischemic heart diseases.
Export Options
About this article
Cite this article as:
Tsang Sharon, Liu Jing and Ming Wong Tak, Testosterone and Cardioprotection Against Myocardial Ischemia, Cardiovascular & Hematological Disorders-Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152907780830888
DOI https://dx.doi.org/10.2174/187152907780830888 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combinations of Renin-Angiotensin-Aldosterone System Antagonists:True Advantages?
Current Pharmaceutical Design The Role of Platelets in Bone Remodeling
Inflammation & Allergy - Drug Targets (Discontinued) Dietary Salt and Disease Prevention: A Global Perspective
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Soluble Epoxide Hydrolase, a Target with Multiple Opportunities for Cardiovascular Drug Discovery
Current Topics in Medicinal Chemistry Treating Nonthyroidal Illness Syndrome in the Critically Ill Patient: Still a Matter of Controversy
Current Drug Targets Epidemiological Evidence Associating Secondhand Smoke Exposure with Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued) ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology Pharmacologic Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design Modulation of Inflammatory Response Improves Myocardial Infarct Healing in Rats
Current Pharmaceutical Design Peptide Receptor Radionuclide Therapy with Somatostatin Analogues in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Relationship between Augmentation Index and Wall Thickening Fraction during Hypotension in an Animal Model of Myocardial Ischemia-Reperfusion and Heart Failure
Current Hypertension Reviews Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets From Protein-Protein Interactions to Rational Drug Design: Are Computational Methods Up to the Challenge?
Current Topics in Medicinal Chemistry Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Vascular Effects of Insulin and Their Relation to Endothelial Dysfunction, Insulin Resistance and Hypertension
Current Hypertension Reviews Heart Valve Lesions In The Antiphospholipid Syndrome
Current Rheumatology Reviews Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions
Current Topics in Medicinal Chemistry Use of Bromine-76 and Iodine-123 Radiohalogenated Tracers in the Drug Development Process
Current Pharmaceutical Design